Aeolus Pharmaceuticals Inc Receives $125,000 Series D Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7f5b0b7a-2b0e-4ed6-950b-c1d978c13ff7&Preview=1 -
Date
11/4/2008 -
Company Name
Aeolus Pharmaceuticals Inc -
Mailing Address
23811 Iverness Place Laguna Niguel, CA 92677 -
Company Description
Aeolous Pharmaceutical is a biopharmaceutical company that is developing a new class of catalytic antioxidant compunds, referred to as manganoporphyrins, for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Over the past decade, Aeolus has synthesizec, developed, and analyzed approximately 200 proprietary catalytic antioxidant compounds, all of which have the same core chemical structure. -
Website
http://www.incara.com -
Transaction Type
Venture Equity -
Transaction Amount
$125,000 -
Transaction Round
Series D -
Proceeds Purposes
The Company expects to use the net proceeds of $120,000 that it raised today from this financing to advance the development of AEOL 10150 and for general administrative expenses and working capital. -
M&A Terms
-
Venture Investor
Undisclosed
